1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

08 Apr 2024
Admin
News Article

Caris Partners with Merck KGaA for ADC Development

Caris enters partnership with Merck KGaA to discover novel cancer targets and accelerate first-in-class ADC development

Overview

Caris Discovery, the therapeutic research arm of Caris Life Sciences (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, announced a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the US and Canada, to accelerate the discovery and development of first-in-class antibody-drug conjugates (ADC) for cancer patients.

Words from CBO: Caris

“We are thrilled to join forces with Merck KGaA, Darmstadt, Germany, to discover targets with the first-in-class potential to advance the next wave of transformational ADC therapeutics,” said Brian Lamon, PhD, chief business officer of Caris.
“This partnership adds to our portfolio of external pipeline programs and is a strong validation of our highly differentiated, orthogonal multi-omics approach to discovering truly novel targets that may be harnessed to eradicate tumours.”

Terms of the Agreement

Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Caris with an upfront payment as well as research funding.
In addition, Caris will be eligible for discovery, development, regulatory and sales-based milestone payments that may total up to $1.4 billion along with tiered royalties.
Merck KGaA, Darmstadt, Germany will receive an exclusive global license to develop, manufacture and commercialize ADC therapeutics for selected targets.

Words from Merck KGaA

“We are dedicated to addressing high unmet needs across multiple cancer types,” said Paul Lyne, global head of research unit oncology for the healthcare business sector of Merck KGaA, Darmstadt, Germany.
“Through close collaboration with Caris, utilizing their unique discovery platform, we complement our internal ADC capabilities to develop novel first-in-class ADCs and ultimately strengthen our potential to expand our oncology portfolio.”

Caris Discovery

Caris Discovery leverages the scale of Caris’ core molecular profiling business to discover novel, druggable targets that would be otherwise inaccessible through more traditional approaches.
Through the convergence of its proprietary ADAPT Biotargeting platform, a contemporaneous patient tissue repository, a suite of sophisticated AI and machine learning capabilities, and its dedicated 59,000 square foot discovery research laboratory, Caris Discovery aims to identify and validate new therapeutic targets that can be harnessed by its biopharma partners to develop the next generation of oncology therapies.

Impact of Partnership

Under this partnership, targets discovered and validated by Caris can be pursued by Merck KGaA, Darmstadt, Germany.
Merck KGaA, Darmstadt, Germany will be responsible for the preclinical and clinical research, as well as the development and commercialization of drug candidates emanating from these programmes.

Words from CSO: Caris

“Caris Discovery is uncovering novel unexplored targets in patient populations where precision therapeutics have yet to be developed,” said Milan Radovich, PhD, senior vice president and chief scientific officer at Caris.
“We are proud to be working closely with Merck KGaA, Darmstadt, Germany, to bring new therapeutic options to cancer patients together.”

Caris Life Sciences

Caris Life Sciences (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!